tetano
Editor, Senior Moderator
Curr Rheumatol Rev. 2017 May 17. doi: 10.2174/1573397113666170517155443. [Epub ahead of print]
[h=1]Vasculitis following influenza vaccination: A review of the literature.[/h] Watanabe T[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Influenza vaccine is safe and effective for the general population as well as for patients with autoimmune diseases. However, although rare, vasculitis has been reported as an adverse event following influenza vaccination.
[h=4]OBJECT:[/h] The aims of this literature review were to identify patients who developed vasculitis following influenza vaccination and to clarify the clinical manifestations of vasculitis in these patients.
[h=4]METHODS:[/h] Using the PubMed database and search engine, we performed a search of the English-language literature by combining the term influenza vaccination with each term for a specific form of vasculitis from January 1966 through April 2016.
[h=4]RESULTS:[/h] A total of 65 patients who developed vasculitis after influenza vaccination were identified from 45 published reports. The majority of patients were elderly, and the patients were predominantly female. The vasculitides included large vessel vasculitis (13 patients), medium vessel vasculitis (2), small vessel vasculitis (42), single organ vasculitis (5), vasculitis associated with systemic disease (1), and vasculitis associated with probable etiology (1). Although the majority of patients achieved complete recovery or remission, there were 3 deaths in patients with ANCA-associated vasculitis and severe long-term sequelae developed in 3 patients (1 with granulomatosis with polyangiitis, 1 with IgA vasculitis and I with unclassified small vessel vasculitis).
[h=4]CONCLUSION:[/h] Since the incidence of vasculitis following influenza vaccination was found to be extremely low, routine influenza vaccination should not be restricted. However, influenza vaccine should not be repeated for patients with ANCA-associated vasculitis following influenza vaccination or with post-influenza vaccination-reactivated IgA vasculitis.
Copyright? Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
[h=4]KEYWORDS:[/h] Vasculitis; adverse event; autoimmunity; immunization; influenza; vaccination; vaccine
PMID: 28521688 DOI: 10.2174/1573397113666170517155443
[h=1]Vasculitis following influenza vaccination: A review of the literature.[/h] Watanabe T[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Influenza vaccine is safe and effective for the general population as well as for patients with autoimmune diseases. However, although rare, vasculitis has been reported as an adverse event following influenza vaccination.
[h=4]OBJECT:[/h] The aims of this literature review were to identify patients who developed vasculitis following influenza vaccination and to clarify the clinical manifestations of vasculitis in these patients.
[h=4]METHODS:[/h] Using the PubMed database and search engine, we performed a search of the English-language literature by combining the term influenza vaccination with each term for a specific form of vasculitis from January 1966 through April 2016.
[h=4]RESULTS:[/h] A total of 65 patients who developed vasculitis after influenza vaccination were identified from 45 published reports. The majority of patients were elderly, and the patients were predominantly female. The vasculitides included large vessel vasculitis (13 patients), medium vessel vasculitis (2), small vessel vasculitis (42), single organ vasculitis (5), vasculitis associated with systemic disease (1), and vasculitis associated with probable etiology (1). Although the majority of patients achieved complete recovery or remission, there were 3 deaths in patients with ANCA-associated vasculitis and severe long-term sequelae developed in 3 patients (1 with granulomatosis with polyangiitis, 1 with IgA vasculitis and I with unclassified small vessel vasculitis).
[h=4]CONCLUSION:[/h] Since the incidence of vasculitis following influenza vaccination was found to be extremely low, routine influenza vaccination should not be restricted. However, influenza vaccine should not be repeated for patients with ANCA-associated vasculitis following influenza vaccination or with post-influenza vaccination-reactivated IgA vasculitis.
Copyright? Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
[h=4]KEYWORDS:[/h] Vasculitis; adverse event; autoimmunity; immunization; influenza; vaccination; vaccine
PMID: 28521688 DOI: 10.2174/1573397113666170517155443